Tesamorelin in Canada: A Researcher’s Buying Guide
Tesamorelin has a genuine pharmaceutical history. A stabilised analogue of growth hormone releasing hormone (GHRH), it was developed clinically under the name Egrifta, and that pedigree shows in how much published data exists around it. For researchers in Canada the practical questions are simpler: where to source it domestically, how it is supplied and handled, and how it fits alongside the other compounds that act on the same pathway.
View product →At a glance: Vistara Labs stocks tesamorelin in 10 mg vials, independently tested, with a certificate of analysis on our Lab Reports page, shipped from within Canada by Canada Post Xpresspost, with same-business-day dispatch on orders before 3 pm Pacific. We deliver to every province, including Ontario, Quebec, British Columbia and Alberta.
What makes tesamorelin different from native GHRH
Natural GHRH is a 44 amino acid peptide with a very short half life. The enzyme dipeptidyl peptidase-4 (DPP-4) cleaves it within minutes, which makes the native molecule difficult to work with in any sustained way. Tesamorelin carries a trans-3-hexenoyl group attached to the N terminus, and that modification is what blocks the DPP-4 cleavage site. The result is a molecule with the same receptor target as GHRH but a usefully longer window before degradation. The full mechanism is covered in our tesamorelin research note.
GHRH analogues and ghrelin mimetics are not interchangeable
This is the distinction that most often causes confusion when researchers first group these compounds together. Tesamorelin, sermorelin and CJC-1295 are GHRH analogues: they bind the GHRH receptor. Ipamorelin and the other growth hormone secretagogues bind the ghrelin receptor instead, a separate receptor reached by a separate route. Two compounds can both be described as acting on the growth hormone axis and still be doing mechanistically different things, which matters a great deal when a study is designed around one pathway rather than the other. It is also why CJC-1295 and ipamorelin are commonly studied together rather than as substitutes for each other.
Why researchers source tesamorelin domestically
Tesamorelin is usually studied over a series of experiments, so a dependable domestic supply is the practical choice, and a lyophilised peptide keeps best when it moves promptly from cold storage to the bench. Tesamorelin (10 mg, lyophilised) is held in stock here with free shipping on larger orders, and every order ships from within Canada, so there is no customs step (see peptides, customs and domestic shipping).
Buying tesamorelin in Canada
- Published certificates. Certificates of analysis from independent laboratories are published for each compound, and tesamorelin’s certificate reports purity above 99 percent, measured by chromatography. It is listed on our lab reports page alongside every other compound we stock.
- Format. Tesamorelin is supplied lyophilised in a sealed vial and reconstituted with bacteriostatic water for laboratory use. If that step is new, see our bacteriostatic water explainer and the tesamorelin reconstitution guide.
- A Canadian team. Questions about any order, from format to handling, go to our team in Canada through the contact page.
- Research-use framing. In Canada these compounds are supplied strictly for laboratory research, and Vistara Labs supplies tesamorelin on that basis; see our guide to the legal landscape.
The same lab reports page carries the certificates for CJC-1295 with ipamorelin and for ipamorelin on its own, the compounds researchers most often weigh against tesamorelin.
Handling and storage
Tesamorelin arrives as a lyophilised powder, which is the stable form. Unopened vials are kept cold and protected from light until they are needed. Once reconstituted, the solution is refrigerated and the vial is labelled with the date and the concentration chosen, because a vial that is not labelled becomes an unknown within a week. General storage practice for research peptides is covered in how to store research peptides.
Where tesamorelin sits among the GH-pathway compounds
Researchers comparing GHRH analogues usually weigh tesamorelin against CJC-1295 with ipamorelin, and that comparison is written up here. The wider compound family sits on the hormonal and growth hormone research page.
Frequently asked questions
Where can I buy tesamorelin in Canada?
From domestic research suppliers. Vistara Labs stocks tesamorelin in Canada and ships from within the country, with its certificate of analysis published on the lab reports page.
Is tesamorelin legal in Canada?
It is supplied for laboratory research use only, the same framing as other research peptides. It is not sold for human use, and nothing here is medical advice.
How is tesamorelin supplied?
As a 10 mg lyophilised powder in a sealed vial, third party tested, with the purity figure published on the product page and in the lab reports table.
What is the difference between tesamorelin and sermorelin?
Both are GHRH analogues, so both target the same receptor. Sermorelin corresponds closely to the first 29 amino acids of native GHRH, while tesamorelin carries the trans-3-hexenoyl modification that resists DPP-4 degradation. The practical difference researchers care about is stability rather than target.
Is tesamorelin the same kind of compound as ipamorelin?
No. Tesamorelin is a GHRH analogue and binds the GHRH receptor. Ipamorelin is a growth hormone secretagogue and binds the ghrelin receptor. They are often discussed together because both relate to the growth hormone axis, but they act through different receptors.
All products discussed are for laboratory research use only and are not for human use. Nothing on this page is medical advice, and no statement about any compound is a claim of therapeutic benefit.
References
Tesamorelin has been studied in randomised placebo-controlled trials measuring body composition and liver fat directly.
- Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extensionRandomised placebo-controlled trial with safety extension; 404 people with HIV-associated abdominal fat accumulation.
- Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trialRandomised, double-blind, multicentre trial in people with HIV and non-alcoholic fatty liver disease, 12 months.
Links open the study record on PubMed so the source can be checked directly. Listing a study is not a claim that its findings apply to any other use, product or route of administration. Research use only.
